— Etanercept (Enbrel®) therapy may be a less costly option than infliximab combined with methotrexate for the treatment of rheumatoid arthritis, according to new research.
The study was presented here this week at the Annual European Congress of Rheumatology (EULAR). Daniel C. Malone, PhD, of the College of Pharmacy at the University of Arizona, United States, and colleagues compared the cost-effectiveness of monotherapy with etanercept 25 mg twice-weekly compared to infliximab 3 mg/kg or 10 mg/kg every four to eight weeks plus methotrexate.
They obtained clinical data on the drugs from the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) trial for infliximab and the Etanercept Therapy in Rheumatoid Arthritis (ERA) trial for etanercept. Dr. Malone’s team based medication costs on United States wholesale prices, and the primary analysis was conducted for a patient weighing 74kg, which is the average weight of persons in the United States.
Based on the results of clinical studies, the investigators estimate that 63 percent of patients taking etanercept monotherapy have no radiographic progression of their disease over two years, compared to only 43 to 54 percent of patients taking various doses infliximab.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!